(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)
Louvain-la-Neuve, Belgium, September 8, 2026 06:00 PM
Summary of the notification
IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on August 31, 2026.
In its notification, Axxion S.A. indicated that it had crossed below the 1% threshold on August 27, 2026 following an acquisition or disposal of securities or voting rights.
Content of the notification
| Name | Address (for legal entities) |
| Axxion S.A. | 15, rue de Flaxweiler, 6776 Grevenmacher, Luxembourg |
| A) Voting rights | Previous notification | After the transaction | |||
| # of voting rights | # of voting rights | % of voting rights | |||
| Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |
| Axxion S.A. | 632,728 | 364,041 | 0 | 0.90% | 0.00% |
| Subtotal | 364,041 | 0 | 0.90% | 0.00% | |
| TOTAL | 364,041 | 0 | 0.90% | 0.00% | |
| B) Equivalent financial instruments | After the transaction | |||||
| Holders of equivalent financial instruments | Type of financial instrument | Expiration date | Exercise period or date | # of voting rights that may be acquired if the instrument is exercised | % of voting rights | Settlement |
| Axxion S.A. | Option Put 16.50 | 18-09-2026 | American | 10,000 | 0.02% | cash |
| Axxion S.A. | Option Put 17.00 | 18-09-2026 | American | 10,000 | 0.02% | cash |
| Axxion S.A. | Option Put 16.00 | 16-10-2026 | American | 10,000 | 0.02% | cash |
| TOTAL | 30,000 | 0.07% | ||||
| TOTAL (A & B) | # of voting rights | % of voting rights |
| 394,041 | 0.97% |
Axxion S.A. is not controlled.
About IBA IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
For further information, please contact:
Elena De Landy Paralegal: Corporate Affairs and Insurance Legal@iba-group.com
Attachment